Janet Hammond - Jan 31, 2024 Form 4 Insider Report for Atea Pharmaceuticals, Inc. (AVIR)

Role
Chief Development Officer
Signature
/s/ Andrea Corcoran, as Attorney-in-Fact for Janet Hammond
Stock symbol
AVIR
Transactions as of
Jan 31, 2024
Transactions value $
-$53,913
Form type
4
Date filed
2/2/2024, 09:24 PM
Previous filing
Feb 2, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVIR Common Stock Options Exercise +46.8K +1806.25% 49.4K Jan 31, 2024 Direct F1, F2
transaction AVIR Common Stock Sale -$53.9K -14K -28.4% $3.84 35.4K Feb 1, 2024 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVIR Restricted Stock Units Options Exercise $0 -46.8K -33.33% $0.00 93.6K Jan 31, 2024 Common Stock 46.8K Direct F1, F4
transaction AVIR Stock Option (Right to Buy) Award $0 +225K $0.00 225K Jan 31, 2024 Common Stock 225K $4.16 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2 Includes 2,591 additional shares acquired under the Atea Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan.
F3 Shares were sold solely to cover taxes upon the vesting of restricted stock units pursuant to a standing Rule 10b5-1 instruction dated March 14, 2022.
F4 The original grant of 140,400 RSUs vested or will vest in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs are fully vested on January 31, 2026.
F5 The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2024 such that the option is fully vested on January 31, 2028.